MX365387B - Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. - Google Patents

Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.

Info

Publication number
MX365387B
MX365387B MX2015003150A MX2015003150A MX365387B MX 365387 B MX365387 B MX 365387B MX 2015003150 A MX2015003150 A MX 2015003150A MX 2015003150 A MX2015003150 A MX 2015003150A MX 365387 B MX365387 B MX 365387B
Authority
MX
Mexico
Prior art keywords
specific antibodies
amyloid polypeptide
islet amyloid
human islet
hiapp
Prior art date
Application number
MX2015003150A
Other languages
English (en)
Other versions
MX2015003150A (es
Inventor
Grimm Jan
Heitz Fabrice
Cheng Feng
Combaluzier Ioana
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of MX2015003150A publication Critical patent/MX2015003150A/es
Publication of MX365387B publication Critical patent/MX365387B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

La presente invención se refiere a un polipéptido amiloide de isleta humano, también conocido como amilina e IAPP y prolAPP, respectivamente, anticuerpos específicos, así como fragmentos, derivados y variantes del mismo, así como métodos relacionados con el mismo. También se describen ensayos, equipos, y soportes sólidos relacionados con los anticuerpos específicos para IAPP y/o prolAPP. El anticuerpo, cadena(s) de inmunoglobulina, así como fragmentos de unión, derivados y variantes del mismo se pueden utilizar en composiciones farmacéuticas u de diagnóstico para inmunoterapia y diagnóstico activada por IAPP y/o prolAPP, respectivamente.
MX2015003150A 2012-09-12 2013-09-12 Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. MX365387B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700110P 2012-09-12 2012-09-12
EP12184134 2012-09-12
PCT/EP2013/068907 WO2014041069A1 (en) 2012-09-12 2013-09-12 Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2015003150A MX2015003150A (es) 2015-12-16
MX365387B true MX365387B (es) 2019-05-31

Family

ID=46832278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003150A MX365387B (es) 2012-09-12 2013-09-12 Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.

Country Status (18)

Country Link
US (4) US9475866B2 (es)
EP (1) EP2895512B1 (es)
JP (2) JP6225189B2 (es)
KR (1) KR102117969B1 (es)
CN (2) CN104812774B (es)
AU (1) AU2013314301B2 (es)
CA (1) CA2884581C (es)
DK (1) DK2895512T3 (es)
EA (1) EA201590459A1 (es)
ES (1) ES2687520T3 (es)
HR (1) HRP20181398T1 (es)
LT (1) LT2895512T (es)
MX (1) MX365387B (es)
PL (1) PL2895512T3 (es)
RS (1) RS57807B1 (es)
SI (1) SI2895512T1 (es)
SM (1) SMT201800512T1 (es)
WO (1) WO2014041069A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HRP20181398T1 (hr) 2012-09-12 2018-10-19 Neurimmune Holding Ag Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba
WO2015004632A1 (en) * 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015083125A2 (en) * 2013-12-06 2015-06-11 Prothena Biosciences Limited Antibodies that recognize iapp
CA2942120A1 (en) * 2014-03-12 2015-09-17 Neurimmune Holding Ag Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced .beta.-cell damage and impaired glucose tolerance
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR101893244B1 (ko) * 2015-05-22 2018-08-30 가천대학교 산학협력단 당뇨병에 대한 신규 바이오마커 및 그의 용도
WO2017075145A1 (en) * 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
CN106279414A (zh) * 2016-08-31 2017-01-04 天津医科大学总医院 人源性抗胰淀素抗体及其制备方法
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CA3120066A1 (en) 2018-11-14 2020-05-22 University Of Kentucky Research Foundation Diagnosis of diabetes by detecting aggregated amylin in erythrocytes
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
AU2021328265A1 (en) * 2020-08-18 2023-04-20 The Regents Of The University Of California Methods and compositions for diabetes treatment and beta-cell regeneration
KR102549520B1 (ko) 2021-01-29 2023-07-03 일리미스테라퓨틱스 주식회사 비염증성 식세포작용 유도 활성을 갖는 융합분자
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
DE60143798D1 (de) * 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
JP2006506942A (ja) 2002-01-31 2006-03-02 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
MXPA04010255A (es) * 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
WO2003092619A2 (en) * 2002-04-30 2003-11-13 Wyeth Holdings Corporation Prevention and treatment of type 2 diabetes
CA2530927A1 (en) * 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
CN1980954A (zh) * 2004-02-11 2007-06-13 安米林药品公司 胰岛淀粉样多肽家族肽及其制备和使用方法
US20080004211A1 (en) * 2004-02-23 2008-01-03 Paul Fraser Inhibitors of Amyloid Fibril Formation and Uses Thereof
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
GB0501348D0 (en) * 2005-01-24 2005-03-02 Zyentia Ltd Compositions and methods
WO2009013543A2 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to kdr and uses thereof - 035
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
EP2575859B1 (en) * 2010-06-03 2018-09-19 Ramot at Tel Aviv University, Ltd. Methods of treating diabetes and compositions capable of same
HRP20181398T1 (hr) 2012-09-12 2018-10-19 Neurimmune Holding Ag Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba

Also Published As

Publication number Publication date
JP6225189B2 (ja) 2017-11-01
JP2018057381A (ja) 2018-04-12
KR20150043562A (ko) 2015-04-22
PL2895512T3 (pl) 2018-11-30
LT2895512T (lt) 2018-09-25
US20160376354A1 (en) 2016-12-29
WO2014041069A1 (en) 2014-03-20
CN104812774B (zh) 2020-11-06
DK2895512T3 (en) 2018-10-15
JP2015535682A (ja) 2015-12-17
CA2884581C (en) 2024-01-23
ES2687520T3 (es) 2018-10-25
EP2895512B1 (en) 2018-07-04
AU2013314301B2 (en) 2018-02-15
CN112225808A (zh) 2021-01-15
EA201590459A1 (ru) 2015-11-30
US9475866B2 (en) 2016-10-25
HK1210185A1 (en) 2016-04-15
EP2895512A1 (en) 2015-07-22
RS57807B1 (sr) 2018-12-31
KR102117969B1 (ko) 2020-06-04
CA2884581A1 (en) 2014-03-20
CN104812774A (zh) 2015-07-29
US10072074B2 (en) 2018-09-11
SMT201800512T1 (it) 2018-11-09
US10882902B2 (en) 2021-01-05
AU2013314301A1 (en) 2015-04-16
HRP20181398T1 (hr) 2018-10-19
US20150210759A1 (en) 2015-07-30
SI2895512T1 (sl) 2018-10-30
MX2015003150A (es) 2015-12-16
US20210107972A1 (en) 2021-04-15
US20180346558A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
PH12021550083A1 (en) Human anti-tau antibodies
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
MX345092B (es) Anticuerpos anti-tau humanos,.
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
AU2011343161A8 (en) Human anti-SOD1 antibodies
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
TN2014000120A1 (en) Cd27l antigen binding proteins
TN2015000247A1 (en) Bcma antigen binding proteins
SG178886A1 (en) Humanized anti-cdcp1 antibodies
SG10201902850TA (en) Human-derived anti-dipeptide repeats (dprs) antibody
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.
CY1120686T1 (el) Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων

Legal Events

Date Code Title Description
FG Grant or registration